Proxalutamide reduces SARS-CoV- 2 infection and associated inflammatory response.

MLA

Yuanyuan Qiao, et al. “Proxalutamide Reduces SARS-CoV- 2 Infection and Associated Inflammatory Response.” Proceedings of the National Academy of Sciences of the United States of America, vol. 120, no. 30, July 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1073/pnas.2221809120.

APA

Yuanyuan Qiao, Wotring, J. W., Yang Zheng, Zhang, C. J., Yuping Zhang, Xia Jiang, Pretto, C. D., Eyunni, S., Parolia, A., Tongchen He, Caleb Cheng, Xuhong Cao, Rui Wang, Fengyun Su, Ellison, S. J., Yini Wang, Jun Qin, Honghua Yan, Qianxiang Zhou, & Liandong Ma. (2023). Proxalutamide reduces SARS-CoV- 2 infection and associated inflammatory response. Proceedings of the National Academy of Sciences of the United States of America, 120(30), 1–10. https://doi.org/10.1073/pnas.2221809120

Chicago

Yuanyuan Qiao, Jesse W. Wotring, Yang Zheng, Charles J. Zhang, Yuping Zhang, Xia Jiang, Carla D. Pretto, et al. 2023. “Proxalutamide Reduces SARS-CoV- 2 Infection and Associated Inflammatory Response.” Proceedings of the National Academy of Sciences of the United States of America 120 (30): 1–10. doi:10.1073/pnas.2221809120.